Current status of new drugs for the treatment of patients with multiple myeloma

Internal Medicine Journal

Volumn 36, Issue 12, 2006, Pages 781-789

  Kenealy, M ^a   Prince, H M ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bortezomib; Lenalidomide; Multiple myeloma; Thalidomide; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DEXAMETHASONE; ENOXAPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; THALIDOMIDE; VINCRISTINE; WARFARIN;

ANEMIA; BONE DISEASE; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; IMMUNOSURVEILLANCE; LETHARGY; LUNG EMBOLISM; MALAISE; META ANALYSIS; MULTIPLE MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; VARICELLA ZOSTER VIRUS; VENOUS THROMBOEMBOLISM; VIRUS REACTIVATION; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE;

EID: 33750626750     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01218.x     Document Type: Review

References (70)

1. Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005; 46: 951-66.
2. Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-20.
3. Attal M, Harousseau JL, Stoppa A, Sotto J, Fuzibet J, Rossi J et al. The Intergroupe Francais du Myelome, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
4. Child JA, Morgan GJ, Davies FE, Owen R, Bell S, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. Medical Research Council Adult Leukaemia Working Party. N Engl J Med 2003; 348: 1875-83.
5. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-42.
6. Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Intergroupe Francophone du Myélome (IFM) Group. Blood 2006; 107: 1292-8.
7. Dewald G, Therneau T, Larson D, Lee YK, Fink S, Smoley S et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005; 106: 3553-8.
8. Moreau P, Facon T, Leleu T, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-83.
9. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel P, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 264: 1546-58.
10. Hideshima T, Anderson K. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002; 2: 927-37.
11. Hideshima T, Chauhan D, Shima Y, Raje N, Davies F, Tai Y-T et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-50.
12. Anderson K. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Semin Hematol 2005; 42: S3-S8.
13. Singhal S, Mehta J, Desikan R, Ayers D, Robertson P, Eddlemon P et al. Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.
14. Mileshkin L, Biagi J, Mitchell P, Underhill C, Grigg A, Bell R et al. A multi-centre phase II trial of thalidomide in relapsed/refractory multiple myeloma reveals an adverse prognostic impact of advanced age. Blood 2003; 102: 69-77.
15. Yakoub-Agha I, Attal M, Dumontet C, Delannoy V, Moreau P, Berthou C et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone due Myeloma (IFM). Hematol J 2002; 3: 185-92.
16. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho A et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377-82.
17. Glasmacher A, Hahn C, Hoffmann F. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584-93.
18. Prince HM, Adena M, Smith DK, Hertel J. Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review [abstract]. Blood 2005; 106: 5160.
19. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318-24.
20. Dimopoulos M, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiannouris C et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-5.
21. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318-24.
22. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-71.
23. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732-9.
24. Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A et al. Thalidomide in the management of multiple myeloma. Semin Hematol 2001; 38: 250-59.
25. Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho A et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001; 98: 3846-8.
26. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-17.
27. García-Sanz R, González-Porras J, Hernández J, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856-63.
28. Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81: 889-95.
29. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
30. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-31.
31. Rajkumar S, Hayman S, Gertz M, Dispenzieri A, Lacy M, Greipp P et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-23.
32. Rajkumar S, Blood E, Vesole D, Fonseca R, Greipp P. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-6.
33. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35-9.
34. Richardson P, Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma [editorial]. J Clin Oncol 2006; 24: 334-6.
35. Barlogie B, Tricot G, Anaissie E, Shaughnessy T, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-30.
36. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 2006; 367: 825-31.
37. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs M et al. Results of amulticenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 2004; 10: 8170-76.
38. Alexanian R, Weber D, Giralt S, Delasalle K. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Ann Oncol 2002; 13: 1116-19.
39. Attal M, Harousseau JL, Leyvraz S, Doyen C, Huylin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; First Edition Paper, prepublished online July 27, 2006.
40. Mileshkin L, Stark R, Day B, Seymour J, Zeldis J, Prince HM. The development of neuropathy in patients with myeloma treated with thalidomide - patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006 (in press).
41. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddlemon P, Fink L et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma Myeloma 2003; 4: 32-5.
42. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
43. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715-21.
44. Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yannaki E et al. Aspirin decreases the thrombotic complications induced by thalidomide when combined with anthracycline based chemotherapy regimens for the treatment of multiple myeloma. Mayo Clin Proc 2005; 80: 1568-74.
45. Rajkumar S. Thalidomide therapy and deep venous thrombosis in multiple myeloma [editorial]. Mayo Clin Proc 2005; 80: 1549-51.
46. Anderson K. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 2005; 42: S3-S8.
47. Zeldis J, Williams B, Thomas S, Elsayed M. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21: 319-30.
48. Richardson P, Blood E, Mitsiades C, Jagannath S, Zeldenrust S, Alsina M et al. A Randomized Phase 2 Study of Lenalidomide Therapy for Patients with Relapsed or Relapsed and refractory Multiple Myeloma. Blood 2006; First Edition Paper, prepublished online July 18, 2006.
49. Richardson P. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Semin Hematol 2005; 42: S9-S15.
50. Dimopoulos M, Spencer A, Attal M et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract]. Blood 2005; 105: 6.
51. Dimopoulos M, Weber D, Chen C, Spencer A, Niesvizky R, Attal M et al. Evaluating oral lenalidomide (Revlimid-) and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma [abstract 0402]. European Haematology Association, 2005.
52. Kenealy M, Prince HM, Spencer A. Lenalidomide (Revlimid) Achieves a High Response Rate in Patients with Relapsed or Refractory Multiple Myeloma: Local Analysis of the International MM010 & MM012 Studies. Haematology Society of Australia and New Zealand Annual Scientific Meeting 2005; abstract 122.
53. Rajkumar S, Hayman S, Lacy M, Dispenzieri A, Geyer S, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-53.
54. Hideshima T, Richardson P, Chauhan D, Palombella V, Elliott P, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
55. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
56. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-72.
57. Richardson P, Barlogie B, Berenson J, Singhal S, Jag S, Irwin D et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma; final time-to-event results from the SUMMIT trial. Cancer 2006; 106: 1316-19.
58. Dubois D, Dhawan R, van de Velde H, Esseltine D, Gupta S, Viala M et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J Clin Oncol 2006; 24: 976-82.
59. Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.
60. Jagannath S, Durie B, Wolf J, Camacho E, Irwin D, Lutzky J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-83.
61. Harousseau JL, Attal M, Leleu X, Gressin R, Hulin C, Fuzibet J-G et al. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study [abstract]. Blood 2004; 104: 1490.
62. Ma MH, Yang HH, Parker K, Manyak S, Friedman J, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-44.
63. Berenson J, Yang H, Sadler K, Jarutirasarn S, Vescio R, Mapes R et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-44.
64. Richardson P, Schlossman R, Munshi N, Avigan D, Jagannath S, Alsina M et al. A phase 1 study of bortezomib (Velcade®) in combination with lenalidomide (Revlimid™) in relapsed and refractory multiple myeloma [abstract 0245]. European Haematology Association, 2005.
65. Wang L, Weber D, Delasalle K, Alexanian R. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma [abstract]. Blood 2004; 104: 210.
66. Zangari M, Barlogie B, Hollmig K, Fassas A, Rasmussen E, Thertulien R et al. Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) [abstract]. Blood 2004; 104: 1480.
67. Kenealy M, Prince M, Honemann D. Tumour lysis syndrome early after treatment with bortezomib in multiple myeloma. Pharmacotherapy 2006; 26: 1205-6.
68. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004; 130: 623-5.
69. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003; 123: 758-69.
70. Velcade. info [homepage on the Internet]. Potential consequences of proteasome inhibition-NFκB. Janssen-Pharmaceutica NV [updated 2 August 2005]. Available from: http://www.velcade.info